This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lim, J. Articles by Yong, E. L. Search for Related Content PubMed PubMed Citation Articles by Lim, J. Articles by Yong, E. L.

Human Androgen Receptor Mutation Disrupts Ternary Interactions between Ligand, Receptor Domains, and the Coactivator TIF2 (Transcription Intermediary Factor 2)

Department of Obstetrics and Gynecology (J.L., F.J.G., E.L.Y.) National University of Singapore Republic of Singapore 119074
Department of Genetics (A.A.R.A., L.P., M.T.) Lady Davis Institute of Medical Research McGill University Montréal, Québec, Canada H3T 1E2

The androgen receptor (AR) is a ligand-dependent X-linked nuclear transcription factor regulating male sexual development and spermatogenesis. The receptor is activated when androgen binds to the C-terminal ligand-binding domain (LBD), triggering a cascade of molecular events, including interactions between the LBD and the N-terminal transactivation domain (TAD), and the recruitment of transcriptional coactivators. A nonconservative asparagine to lysine substitution in AR residue 727 was encountered in a phenotypically normal man with subfertility and depressed spermatogenesis. This N727K mutation, although located in the LBD, did not alter any ligand-binding characteristic of the AR in the patient’s fibroblasts or when expressed in heterologous cells. Nonetheless, the mutant AR displayed only half of wild-type transactivation capacity when exposed to physiological or synthetic androgens. This transactivation defect was consistently present when examined with two different reporter systems in three cell lines, using three androgen-driven promoters (including the complex human prostate-specific antigen promoter), confirming the pathogenicity of the mutation. In mammalian two-hybrid assays, N727K disrupted LBD interactions with the AR TAD and with the coactivator, transcription intermediary factor 2 (TIF2). Strikingly, the transactivation defect of the mutant AR can be rectified in vitro with mesterolone, consistent with the ability of this androgen analog to restore sperm production in vivo. Mesterolone, but not the physiological androgen dihydrotestosterone, restored mutant LBD interactions with the TAD and with TIF2, when expressed as fusion proteins in the two-hybrid assay. Our data support an emerging paradigm with respect to AR mutations in the LBD and male infertility: pathogenicity is transmitted through reduced interdomain and coactivator interactions, and androgen analogs that are corrective in vitro may indicate hormonal therapy.

This article has been cited by other articles:

				M. H. Liu, J. Li, P. Shen, B. Husna, E. S. Tai, and E. L. Yong A Natural Polymorphism in Peroxisome Proliferator-Activated Receptor-{alpha} Hinge Region Attenuates Transcription due to Defective Release of Nuclear Receptor Corepressor from Chromatin Mol. Endocrinol., May 1, 2008; 22(5): 1078 - 1092. [Abstract] [Full Text] [PDF]

				E. Estebanez-Perpina, L. A. Arnold, P. Nguyen, E. D. Rodrigues, E. Mar, R. Bateman, P. Pallai, K. M. Shokat, J. D. Baxter, R. K. Guy, et al. A surface on the androgen receptor that allosterically regulates coactivator binding PNAS, October 9, 2007; 104(41): 16074 - 16079. [Abstract] [Full Text] [PDF]

				J Jaaskelainen, A Deeb, J W Schwabe, N P Mongan, H Martin, and I A Hughes Human androgen receptor gene ligand-binding-domain mutations leading to disrupted interaction between the N- and C-terminal domains. J. Mol. Endocrinol., April 1, 2006; 36(2): 361 - 368. [Abstract] [Full Text] [PDF]

				J. Igarashi-Migitaka, A. Takeshita, N. Koibuchi, S. Yamada, R. Ohtani-Kaneko, and K. Hirata Differential expression of p160 steroid receptor coactivators in the rat testis and epididymis Eur. J. Endocrinol., October 1, 2005; 153(4): 595 - 604. [Abstract] [Full Text] [PDF]

				C. J. Burd, C. E. Petre, H. Moghadam, E. M. Wilson, and K. E. Knudsen Cyclin D1 Binding to the Androgen Receptor (AR) NH2-Terminal Domain Inhibits Activation Function 2 Association and Reveals Dual Roles for AR Corepression Mol. Endocrinol., March 1, 2005; 19(3): 607 - 620. [Abstract] [Full Text] [PDF]

				A. Umar, C. A. Berrevoets, N. M. Van, M. van Leeuwen, M. Verbiest, W. J. Kleijer, D. Dooijes, J. A. Grootegoed, S. L. S. Drop, and A. O. Brinkmann Functional Analysis of a Novel Androgen Receptor Mutation, Q902K, in an Individual with Partial Androgen Insensitivity J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 507 - 515. [Abstract] [Full Text] [PDF]

				Y. A. Elhaji, J. Hui Wu, B. Gottlieb, L. K. Beitel, C. Alvarado, G. Batist, and M. A. Trifiro An Examination of How Different Mutations at Arginine 855 of the Androgen Receptor Result in Different Androgen Insensitivity Phenotypes Mol. Endocrinol., August 1, 2004; 18(8): 1876 - 1886. [Abstract] [Full Text] [PDF]

				S. A. Ghali, B. Gottlieb, R. Lumbroso, L. K. Beitel, Y. Elhaji, J. Wu, L. Pinsky, and M. A. Trifiro The Use of Androgen Receptor Amino/Carboxyl-Terminal Interaction Assays to Investigate Androgen Receptor Gene Mutations in Subjects with Varying Degrees of Androgen Insensitivity J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 2185 - 2193. [Abstract] [Full Text] [PDF]

				C. J. Loy, K. S. Sim, and E. L. Yong Filamin-A fragment localizes to the nucleus to regulate androgen receptor and coactivator functions PNAS, April 15, 2003; 100(8): 4562 - 4567. [Abstract] [Full Text] [PDF]

				S. Dejager, H. Bry-Gauillard, E. Bruckert, B. Eymard, F. Salachas, E. LeGuern, S. Tardieu, R. Chadarevian, P. Giral, and G. Turpin A Comprehensive Endocrine Description of Kennedy's Disease Revealing Androgen Insensitivity Linked to CAG Repeat Length J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3893 - 3901. [Abstract] [Full Text] [PDF]

				E. Holter, N. Kotaja, S. Makela, L. Strauss, S. Kietz, O. A. Janne, J.-A. Gustafsson, J. J. Palvimo, and E. Treuter Inhibition of Androgen Receptor (AR) Function by the Reproductive Orphan Nuclear Receptor DAX-1 Mol. Endocrinol., March 1, 2002; 16(3): 515 - 528. [Abstract] [Full Text] [PDF]

				N. Yoshikawa, Y. Makino, K. Okamoto, C. Morimoto, I. Makino, and H. Tanaka Distinct Interaction of Cortivazol with the Ligand Binding Domain Confers Glucocorticoid Receptor Specificity. CORTIVAZOL IS A SPECIFIC LIGAND FOR THE GLUCOCORTICOID RECEPTOR J. Biol. Chem., February 8, 2002; 277(7): 5529 - 5540. [Abstract] [Full Text] [PDF]

				Y.C. Ong, P.R. Kolatkar, and E.L. Yong Androgen receptor mutations causing human androgen insensitivity syndromes show a key role of residue M807 in Helix 8-Helix 10 interactions and in receptor ligand-binding domain stability Mol. Hum. Reprod., February 1, 2002; 8(2): 101 - 108. [Abstract] [Full Text] [PDF]

				J. Thompson, F. Saatcioglu, O. A. Janne, and J. J. Palvimo Disrupted Amino- and Carboxyl-Terminal Interactions of the Androgen Receptor Are Linked to Androgen Insensitivity Mol. Endocrinol., June 1, 2001; 15(6): 923 - 935. [Abstract] [Full Text] [PDF]

				Q. Wang, J. Lu, and E. L. Yong Ligand- and Coactivator-mediated Transactivation Function (AF2) of the Androgen Receptor Ligand-binding Domain Is Inhibited by the Cognate Hinge Region J. Biol. Chem., March 2, 2001; 276(10): 7493 - 7499. [Abstract] [Full Text] [PDF]